TREATMENT OF TYPE 2 DIABETES MELLITUS USING FIXED COMBINATION OF METFORMIN AND GLIBENCLAMIDE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The urgent task of modern diabetology is search for the optimal therapeutic approach that improves the effectiveness of treatment of patients with type 2 diabetes mellitus (DM). Monotherapy with hypoglycemic drugs does not always Lead to the achievement of target values of glycemia; therefore, it is necessary to intensify therapy with the use of two and three drugs, which Leads to a decrease in the patients compliance. The combination of glibenclamide and metformin is the most interesting. Synergism of the hypoglycemic effect of the components contributes to the achievement of glycemic targets. The use of fixed combination of metformin and glibenclamide improves the clinical and economic effectiveness of type 2 DM treatment and patient adherence to treatment.

Full Text

Restricted Access

About the authors

Aleksandr S. AMETOV

MD, professor, head of the Department of endocrinology, Russian medical academy of continuing professional education. 125315, Moscow, 20 Chasovaya St

Dinara G. GUSENBEKOVA

Email: drdinara@yandex.ru
PhD, endocrinologist of the highest category, City policlinic №219 123480, Moscow, 4 Yana Rainisa bulvar

References

  1. IDF Diabetes Atlas Sixth Edition, International Diabetes Federation.
  2. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. 3-е издание, перераб. и доп. Т. 1. М.: ГЭОТАР-Медиа, 2015. С. 92-119. [Ametov A.S. Type 2 diabetes mellitus. Problems and solutions. 3rd edition. Vol. 1. Moscow: GEOTAR-Media, 2015. P. 92-119 (in Russ.)]
  3. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-12.
  4. Старостина E.Г., Древаль А.В. Бигуаниды в лечении сахарного диабета. Руководство для практического врача. М., 2000. 28 с. [Starostina E.G., Dreval A.V. Biguanides in the treatment of diabetes. A guide for practitioners. M., 2000. 28 p. (in Russ.)]
  5. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann. Intern. Med. 2002;137(1):25-33.
  6. Дедов И.И., Шестакова М.В. Сахарный диабет. Диагностика, лечение, профилактика. М., 2011. 372 с. [Dedov I.I., Shestakova M.V. Diabetes mellitus. Diagnosis, treatment, prevention. M., 2011. 372 p. (in Russ.)]
  7. Berthier A., Paya M., Garcia-Cabrero A.M., Ballester M.I., Heredia M., Serratosa J.M. Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease. Mol. Neurobiol. 2016;53(2):1296-309.
  8. Chung M.M., Chen Y.L., Pei D., Cheng Y.C., Sun B., Nicol C.J., Yen C.H., Chen H.M., Liang Y.J., Chiang M.C. The neuroprotective role of 15 metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim. Biophys. Acta. 2015;1852(5):720-73.
  9. Su T., Liao B., Dong Y., Peng Z., Zhou Q., Li B., Peng S., Zhang N. Effect of metformin on colorectal carcinoma in type 2 diabetes mellitus patients: a Markov model analysis. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20(6):689-93 (in Chinese).
  10. Currie C.J., Pool C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-77.
  11. Gandini S., Puntoni M., Heckman-Stoddard B.M., Dunn B.K., Ford L., DeCensi A., Szabo E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila.) 2014;7(9):867-85.
  12. Смирнова О.М., Кононенко И.В. Гипогликемическая терапия сахарного диабета 2 типа: проблемы долгосрочной безопасности. Эффективная фармакотерапия. 2016;4-5:34. [Smirnova O.M., Kononenko I.V. Hypoglycemic therapy of type 2 diabetes mellitus: problems of long-term safety. Effective pharmacotherapy. 2016;4-5:34 (in Russ.)]
  13. Калашникова М.Ф., Белоусов Д.Ю., Сунцов Ю.И., Кантемирова М.А., Дедов И.И. Фармакоэпидемиологический анализ потребления сахароснижающих лекарственных препаратов у больных сахарным диабетом в городе Москве. Сахарный диабет. 2015; 18(2):32-46. [Kalashnikova M.F., Belousov D.Yu., Suntsov Yu.I., Kantemirova M.A., Dedov 1.1. Pharmacoepidemiological analysis of consumption of hypoglycemic drugs in diabetic patients in the city of Moscow. Diabetes. 2015;18(2):32-46 (in Russ.)]
  14. Колода Д.Е. Эндокринология. Национальное руководство. М., 2009. 203 с. [Koloda D.Ye. Endocrinology. National guidelines. Moscow, 2009. 203 p. (in Russ.)]
  15. H.G. Creuzfeldt-Institute zu Kiel, Kiel, July 2010.
  16. International Gesellschaft fur Praventivmedizin. Berlin, Mai 2012.
  17. Brunetti P., Pagano G., Turco C., Gori M., Perriello G.; Glibo 5 Study Group. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial. Diabetes Nutr. Metab. 2004;17(6):350-7.
  18. Hermann L.S., Schersten B., Bitzen P.O., Kjellstrom T., Lindgarde F., Melander А. Terapeutic comparison of metformin and sulfonylurea alone and various combinations. A double-blind controlled study. Diabetes Care. 1994;17(10):1100-9.
  19. Allavoine T.H., Marre M. Efficasy of fixed combination metformine/glibenclamide in metformin failure type 2 diabetes patients. Diabetes Res. Clin. Pract. 2000;50(Suppl. 1):368.
  20. Melikian C., White T.J., Vanderplas A., Dezii C.M., Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin. Ther. 2002;24(3):460-7.
  21. Tosi F., Muggeo M., Brun E., Spiazzi G., Perobelli L., Zanolin E., Gori M., Coppini A., Moghetti P. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;7:862-86.
  22. Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 8 выпуск. Москва, 2017. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. Algorithms of specialized medical care for patients with diabetes, 8th edition. Moscow, 2017 (in Russ.)]
  23. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies